Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MARAVAI LIFESCIENCES HOLDINGS, INC.

(MRVI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2022 01/12/2022 01/13/2022 01/14/2022 01/18/2022 Date
34.35(c) 33.07(c) 31.33(c) 30.33(c) 27.97(c) Last
1 457 557 1 268 078 1 793 961 1 571 830 1 861 958 Volume
+2.60% -3.73% -5.26% -3.19% -7.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 779 M - -
Net income 2021 299 M - -
Net cash position 2021 101 M - -
P/E ratio 2021 22,5x
Yield 2021 0,25%
Sales 2022 859 M - -
Net income 2022 309 M - -
Net cash position 2022 479 M - -
P/E ratio 2022 18,3x
Yield 2022 -
Capitalization 3 677 M 3 677 M -
EV / Sales 2021 4,59x
EV / Sales 2022 3,72x
Nbr of Employees 460
Free-Float 34,2%
More Financials
Company
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The Company's segments include Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy,... 
Sector
Biotechnology & Medical Research
Calendar
01/28 | 12:00pm
More about the company
Ratings of Maravai LifeSciences Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MARAVAI LIFESCIENCES HOLDINGS, INC.
01/05Maravai LifeSciences Announces Registration and Webcast Information for Upcoming R&D Da..
AQ
01/03MARAVAI LIFESCIENCES HOLDINGS, INC. : Other Events (form 8-K)
AQ
2021MARAVAI LIFESCIENCES HOLDINGS, INC.( : MRVI) added to NASDAQ Biotechnology Index
CI
2021Maravai LifeSciences Holdings to Be Added to Nasdaq Biotechnology Index
MT
2021Maravai LifeSciences Added to the Nasdaq Biotechnology Index
AQ
2021Maravai LifeSciences Announces Establishment of New Charitable Foundation
AQ
2021MARAVAI LIFESCIENCES : Stifel Investor Presentation
PU
2021MARAVAI LIFESCIENCES HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
2021Q3 2021 Maravai LifeSciences Earnings Presentation
PU
2021Maravai LifeSciences Holdings, Inc. Revises Earnings Guidance for the Year 2021
CI
2021Maravai LifeSciences Q3 Earnings, Revenue Jump; Company Lifts Full-Year Outlook
MT
2021MARAVAI LIFESCIENCES REPORTS THIRD QUARTER FINANCIAL RESULTS, UPDATES 2021 FINANCIAL GU..
PU
2021Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q3 Revenue $204.8M, vs...
MT
2021Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q3 EPS $0.44, vs. Stree..
MT
2021Maravai LifeSciences Reports Third Quarter Financial Results, Updates 2021 Financial Gu..
AQ
More news
News in other languages on MARAVAI LIFESCIENCES HOLDINGS, INC.
2021Maravai LifeSciences Holdings sera ajouté à l'indice biotechnologique Nasdaq
2021Maravai LifeSciences Holdings, Inc. révise ses prévisions de bénéfices pour l'année 202..
2021Les résultats et le chiffre d'affaires de Maravai LifeSciences augmentent au troisième ..
2021Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC annonce un chiffre d'affaires d..
2021Maravai LifeSciences Holdings, Inc. fournit des prévisions de résultats pour l'ensemble..
More news
Analyst Recommendations on MARAVAI LIFESCIENCES HOLDINGS, INC.
More recommendations
Chart MARAVAI LIFESCIENCES HOLDINGS, INC.
Duration : Period :
Maravai LifeSciences Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MARAVAI LIFESCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 27,97 $
Average target price 58,13 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Carl W. Hull Chairman & Chief Executive Officer
Kevin M. Herde Chief Financial Officer
Mike Houston Chief Science Officer
Anat Ashkenazi Independent Director
Susannah Gray Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MARAVAI LIFESCIENCES HOLDINGS, INC.-33.25%3 677
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-0.66%54 178
BIONTECH SE-34.36%40 873